CTMX · Insider Trading
CytomX Therapeutics, Inc.
Every open-market purchase and sale reported by CTMX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-05 | Alejandra Carvajal | Chief Legal Officer | A | +100,000 | — |
| 2026-07-30 | Charles S. Fuchs | Director | A | +118,000 deriv. | — |
| 2026-06-22 | Halley E Gilbert | Director | A | +59,000 deriv. | — |
| 2026-06-22 | James R Meyers | Director | A | +59,000 deriv. | — |
| 2026-06-22 | Matthew P. Young | Director | A | +59,000 deriv. | — |
| 2026-06-22 | Mani Mohindru | Director | A | +59,000 deriv. | — |
| 2026-06-22 | Alan Ashworth | Director | A | +59,000 deriv. | — |
| 2026-06-22 | Zhen Su | Director | A | +59,000 deriv. | — |
| 2026-06-22 | Elaine V Jones | Director | A | +59,000 deriv. | — |
| 2026-06-17 | Christopher Ogden | Chief Financial Officer | Sell | −1,624 | −$4.95K |
| 2026-03-19 | Christopher Ogden | Chief Financial Officer | Sell | −19,323 | −$124.11K |
| 2026-03-19 | Yu-Waye Chu | Chief Medical Officer | Sell | −21,279 | −$136.68K |
| 2026-03-19 | Sean A. McCarthy | CEO | Sell | −118,969 | −$764.14K |
| 2026-03-19 | Marcia Belvin | SVP, Chief Scientific Officer | Sell | −31,492 | −$202.27K |
| 2026-02-04 | Christopher Ogden | Chief Financial Officer | A | +90,000 | — |
| 2026-02-04 | Marcia Belvin | SVP, Chief Scientific Officer | A | +60,000 | — |
| 2026-02-04 | Rachael Lester | Chief Business Officer | A | +20,000 | — |
| 2026-02-04 | Sean A. McCarthy | CEO | A | +210,000 | — |
| 2026-02-04 | Yu-Waye Chu | Chief Medical Officer | A | +75,000 | — |
| 2025-11-10 | Sean A. McCarthy | CEO | Sell | −101,793 | −$461.91K |
| 2025-10-29 | Rachael Lester | Chief Business Officer | A | +650,000 deriv. | — |
| 2025-09-30 | Christopher Ogden | Chief Financial Officer | A | +117,400 deriv. | — |
| 2025-09-30 | Marcia Belvin | SVP, Chief Scientific Officer | A | +54,450 deriv. | — |
| 2025-09-30 | Sean A. McCarthy | CEO | A | +855,000 deriv. | — |
| 2025-09-30 | Yu-Waye Chu | Chief Medical Officer | A | +131,250 deriv. | — |
| 2025-06-17 | Sean A. McCarthy | CEO | MIXED | +94,489 | −$149.26K |
| 2025-06-17 | Christopher Ogden | Chief Financial Officer | MIXED | +25,245 | −$33.38K |
| 2025-06-17 | Marcia Belvin | SVP, Chief Scientific Officer | MIXED | +23,616 | −$37.33K |
| 2025-06-13 | Mani Mohindru | Director | A | +38,000 deriv. | — |
| 2025-06-13 | Elaine V Jones | Director | A | +38,000 deriv. | — |
| 2025-06-13 | Alan Ashworth | Director | A | +38,000 deriv. | — |
| 2025-06-13 | Zhen Su | Director | A | +38,000 deriv. | — |
| 2025-06-13 | Halley E Gilbert | Director | A | +38,000 deriv. | — |
| 2025-06-13 | James R Meyers | Director | A | +38,000 deriv. | — |
| 2025-06-13 | Matthew P. Young | Director | A | +38,000 deriv. | — |
| 2025-03-20 | Marcia Belvin | SVP, Chief Scientific Officer | Sell | −19,512 | −$11.69K |
| 2025-03-20 | Christopher Ogden | Chief Financial Officer | Sell | −8,551 | −$5.12K |
| 2025-03-20 | Yu-Waye Chu | Chief Medical Officer | Sell | −4,025 | −$2.41K |
| 2025-03-20 | Lloyd A Rowland | General Counsel | Sell | −10,203 | −$6.11K |
| 2025-03-20 | Sean A. McCarthy | CEO | Sell | −37,656 | −$22.56K |
| 2025-02-10 | Marcia Belvin | SVP, Chief Scientific Officer | A | +92,500 | — |
| 2025-02-06 | Christopher Ogden | Chief Financial Officer | A | +101,500 | — |
| 2025-02-06 | Yu-Waye Chu | Chief Medical Officer | A | +113,500 | — |
| 2025-02-06 | Sean A. McCarthy | CEO | A | +375,000 | — |
| 2025-02-06 | Marcia Belvin | SVP, Chief Scientific Officer | A | +87,500 | — |
| 2024-08-22 | Sean A. McCarthy | CEO | MIXED | +23,602 | −$17.08K |
| 2024-08-22 | Marcia Belvin | SVP, Chief Scientific Officer | MIXED | +7,069 | −$5.14K |
| 2024-08-22 | Christopher Ogden | Chief Financial Officer | MIXED | +4,891 | −$2.44K |
| 2024-08-22 | Lloyd A Rowland | General Counsel | MIXED | +7,069 | −$5.14K |
| 2024-08-22 | Jeffrey B Landau | Chief Business Officer | MIXED | +7,069 | −$5.14K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Sean A. McCarthy | CEO | 1,172,080 | $2.95M |
| Marcia Belvin | SVP, Chief Scientific Officer | 300,760 | $756.41K |
| Christopher Ogden | Chief Financial Officer | 295,324 | $742.74K |
| Yu-Waye Chu | Chief Medical Officer | 189,446 | $476.46K |
| Lloyd A Rowland | General Counsel | 120,594 | $303.29K |
| Alejandra Carvajal | Chief Legal Officer | 100,000 | $251.50K |
| Rachael Lester | Chief Business Officer | 20,000 | $50.30K |
| Elaine V Jones | Director | 5,142 | $12.93K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CTMX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.